[一季报]健康元(600380):健康元药业集团股份有限公司2022年第一季度报告（英文版）
|
时间：2022年04月24日 19:45:44 中财网 |
|
原标题:健康元:健康元药业集团股份有限公司2022年第一季度报告（英文版）
Stock code：600380 Stock abbreviation：健康元
Joincare Pharmaceutical Group Industry Co., Ltd
2022 First Quarterly Report
Board of Directors (the “Board”) and all Directors of the Company hereby warrant that there are no
false representations, misleading statements or material omissions contained in this report, and severally and jointly accept responsibility for the truthfulness, accuracy and completeness of the contents of the Report.
IMPORTANT NOTICE
(I) The Board, the Supervisory Committee and the Directors, Supervisors and senior management of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of quarterly reports, and that there are no false representations, misleading statements or material omissions contained in the Report, and severally and jointly accept responsibility. (II) The person-in-charge of the Company, the person-in-charge of the Company's accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant the truthfulness, accuracy and completeness of the financial statements contained in quarterly reports.
(III) Whether the first quarterly financial statements are audited □Applicable √N/A
(IV) The Report is prepared in both Chinese and English. In case of any ambiguity in the understanding of the Chinese and English texts, the Chinese version shall prevail.
I Principal Financial Data
(I) Principal accounting data and financial indicators
Unit: Yuan Currency: RMB
| Item | The Reporting Period:
(January-March 2022) | Year-on-Year Change (%) | | Revenues | 4,657,343,538.89 | 12.36 | | Net profit attributable to Shareholders of
the listed company | 460,537,813.53 | 25.52 | | Net profit attributable to Shareholders of
the listed company after deducting the
extraordinary gain or loss | 457,193,702.95 | 36.47 | | Net cash flow from operating activities | 871,904,476.98 | 76.27 | | Basic earnings per share (RMB/share) | 0.2411 | 28.49 | | Diluted earnings per share (RMB/share) | 0.2410 | 28.72 | | Weighted average return on net assets (%) | 3.84 | Increased by 0.58 percentage points |
| | End of the
Reporting Period | End of the Previous Year | Change from the end
of the previous year to
the end of the
Reporting Period (%) | | Total assets | 32,275,092,753.15 | 31,103,900,389.29 | 3.77 | | Owners’ equity attributable
to Shareholders of the listed
company | 12,073,975,596.59 | 11,820,293,656.69 | 2.15 |
Note: During the Reporting Period, the Company recorded revenues of RMB 4,657 million, representing an increase of 12.36% year-on-year; the main driver of the growth is steady increasing
sales volume of main product categories in key specialist arenas. During the first quarter of 2022,
Revenues from chemical drug preparation products amounted to RMB 2,737 million, representing an increase of 24.54% year-on-year, of which, Revenues from Inhalation products amounted to 363 million, representing an increase of 324.90% year-on-year; Revenues from anti-infective drugs amounted to RMB 350 million, representing an increase of 26.91% year-on-year; Revenues from gastroenterology products amounted to RMB 1,070 million, representing an increase of 5.90% year-on-year; Revenues from gonadotropic hormones products amounted to RMB 737 million, representing an increase of 22.84% year-on-year; Revenues from APIs and intermediates amounted to RMB 1,406 million, representing an increase of 14.90% year-on-year. The Revenues from traditional Chinese medicine preparations amounted to RMB 283 million, representing a decrease of 33.53% year-on-year. The Revenues from diagnostic reagents and equipment products amounted to RMB162 million, representing a decrease of 30.77% year-on-year.
(II) Items and amounts of extraordinary gains and losses
Unit: Yuan Currency: RMB
| Item | Amounts for the
Reporting Period | Explanation | | Gains and losses on disposal of non-current
assets | -374,417.51 | Proceeds from disposal of fixed
assets | | Government grants included in profit and
loss for the Period (except for government
grants closely associated with normal
corporate businesses, entitled at fixed
amount or fixed level according to national
policies and national unified standards) | 56,644,887.24 | Government grants through the
profits and losses for the Period | | Gains and losses on fair value changes
derived from holding of financial assets held
for trading, derivative financial assets,
financial liabilities held for trading,
derivative financial liabilities, and
investment income generated on disposal of
financial assets held for trading, derivative
financial assets, financial liabilities held for
trading, derivative financial liabilities and
other debt investments, except for effective
hedging activities related to the ordinary
operating business of the Company | -45,275,532.62 | Gains or losses arising from
changes in fair value of financial
assets/liabilities held for trading,
and investment gains from holding
and disposal of financial
assets/liabilities held for trading | | Other non-operating Revenues and non-
operating expenditures apart from the above
items | 241,415.42 | Other non-operating Revenues and
non-operating expenditures apart
from the above items | | Less: Income tax effect | 9,124,665.76 | Effect of the above items on
income tax | | Effect of minority interests after tax | -1,232,423.81 | The portion of the above items to
which minority shareholders are
entitled | | Total | 3,344,110.58 | |
The explanation on the recognitions of the items of extraordinary gains and losses as set out in the
“Interpretative Announcement for Information Disclosure of Companies that Issue Securities to the Public No. 1 – Extraordinary Gains or Losses” as items of recurring gains and losses □Applicable √N/A
(III) Changes and the reasons for changes in principal accounting data and financial indicators √Applicable □N/A
| Name of item | Change in proportion（%） | Explanation | | Net profit attributable to
Shareholders of the listed
company after deducting the
extraordinary gain or loss | 36.47 | Mainly due to the growth of the sales
revenues from the chemical drugs and
APIs products, which is the main driver
of the growth of the net incomes. | | Net cash flow from operating
activities | 76.27 | Mainly due to an increase of cash
collections of sales revenues. |
（IV）Substantial changes of other items in the Financial Statements and financial indicators and reasons thereof
Unit: Yuan Currency: RMB
| Balance Sheet | 2022/03/31 | 2021/12/31 | Change in
proportion
（%） | Main Reason | | Short-term loans | 1,655,807,901.10 | 2,518,484,835.09 | -34.25 | Mainly due to repayment of loans in the Period. | | Contract liabilities | 124,089,632.31 | 234,140,702.29 | -47.00 | Mainly due to part of the contract payments received
in advance in the Period which met the conditions for
revenue recognition were transferred to revenues. | | Taxes payables | 382,548,978.08 | 270,618,183.41 | 41.36 | Mainly due to an increase in enterprise income tax
payables. | | Long-term loans | 1,816,661,809.48 | 826,780,252.78 | 119.73 | Mainly due to an increase of new long-term loans by
subsidiaries in the Period. | | Treasury shares | 472,590,296.96 | 222,644,454.50 | 112.26 | Mainly due to the share repurchased during the current
period. | | Other
comprehensive
income | -87,498,451.08 | 5,387,545.97 | -1724.09 | Mainly due to the disposal of stocks of China Galaxy
Securities Co., Ltd. held during the Period. | | Income Statement | 2022 Jan.-Mar. | 2021 Jan.-Mar. | Change in
proportion
（%） | Main Reason | | Investment incomes | 29,176,808.52 | 21,812,732.70 | 33.76 | Mainly due to the increase in the investment incomes
from associate investments held in the current period. | | Gains from changes
in fair value | -54,151,999.18 | -39,393,074.92 | N/A | Mainly due to fluctuations in the market value of subject
securities investment held. | | Credit impairment
loss | 217,773.10 | -3,611,272.93 | N/A | Mainly due to the recovery of the accounts receivables
with relatively long ages in the current period which
offset the expected credit losses accrued in the previous
period. | | Asset impairment
loss | -5,309,013.21 | -22,802,167.34 | N/A | Mainly due to a decrease in the provision for inventory
depreciation in the current period as compared with the
previous period. | | Gains from disposal
of assets | -370,357.71 | 21,927.78 | -1788.99 | Mainly due to losses occurred from disposal of fixed
assets in the current period. | | Non-operating
income | 2,321,933.96 | 24,072,371.67 | -90.35 | Mainly due to the land disposal in the previous period. | | Non-operating
expenditure | 2,084,578.34 | 3,257,611.14 | -36.01 | Mainly due to larger non-profit donation expenditure in
the previous period. | | Other
comprehensive net
income after
taxation | -106,847,774.60 | -166,618,134.73 | N/A | Mainly due to changes in the fair value of other equity
instrument investments. | | Cash Flow
Statement | 2022 Jan.-Mar. | 2021 Jan.-Mar. | Change in
proportion
（%） | Main Reason | | Net cash flow from
operating activities | 871,904,476.98 | 494,649,514.25 | 76.27 | Mainly due to an increase of cash collections of sales
revenues. | | Net cash flow from
investment
activities | -77,907,837.67 | -269,420,918.38 | N/A | Mainly due to the increase in cash inflow from
investing activities caused by the disposal of stocks of
China Galaxy Securities Co., Ltd. held during the
Period. | | Net cash flow from
financing activities | 62,714,553.34 | -542,754,908.85 | N/A | Mainly due to an increase of new long-term loans in
the current period. | | Effect of changes in
foreign exchange
rates on cash and
cash equivalents | -12,259,201.98 | 3,666,733.44 | -434.34 | Mainly due to an increase of exchange losses on
foreign currency funds held as a result of the
fluctuations in exchange rates. | | Net increase in cash
and cash
equivalents | 844,451,990.66 | -313,859,579.54 | N/A | Mainly due to an increase of cash from daily operating
activities of the Company and an increase of new long-
term loans. |
II Shareholders' Information
(I) Table of the total number of ordinary shareholders, the number of preferred shareholders with resumed voting rights and shareholdings of the top 10 shareholders Unit: Shares
| Total number of ordinary
shareholders at the end of
the Reporting Period | 102,434 | Total number of preferred
shareholders with resumed voting
rights at the end of the Reporting
Period (if any) | 0 | | | | | Shareholdings of the top 10 shareholders | | | | | | | | Name of shareholders | Nature of
shareholders | Number of
shares | Percentage
(%) | Number of
shares held
with selling
restrictions | Pledge, mark or lock-up | | | | | | | | Share
status | Number | | Shenzhen Baiyeyuan
Investment Co., Ltd. * (深圳
市百业源投资有限公司) | Domestic
non-state-
owned legal
person | 895,653,653 | 46.85 | 0 | Pledge | 95,679,725 | | Hong Kong Securities
Clearing Company Limited | Unknown | 127,833,815 | 6.69 | 0 | Unknown | | | Might Seasons Limited | Overseas legal
person | 57,487,434 | 3.01 | 0 | Unknown | | | 108 portfolio of national
social security fund | Unknown | 11,461,721 | 0.60 | 0 | Unknown | | | Huaxia Life Insurance Co.,
Ltd. - proprietary fund | Unknown | 9,275,718 | 0.49 | 0 | Unknown | | | 16011 portfolio of basic
endowment insurance fund | Unknown | 9,050,234 | 0.47 | 0 | Unknown | | | Bosera Funds Management
Co., Ltd. - 419 portfolio of
social security funds | Unknown | 8,732,946 | 0.46 | 0 | Unknown | | | He Zhong | Domestic
natural person | 7,800,024 | 0.41 | 0 | Unknown | | | Abu Dhabi Investment
Authority | Overseas legal
person | 5,417,816 | 0.28 | 0 | Unknown | | | Agricultural Bank of China
Limited - China 500
Exchange Traded Open-End
Index Securities Investment
Fund (ETF) | Unknown | 4,690,194 | 0.25 | 0 | Unknown | |
| Shareholdings of the top 10 shareholders without selling restrictions | | | | | Name of shareholders | Number of tradable
shares held without
selling restrictions | Class and number of shares | | | | | Class | Class | | Shenzhen Baiyeyuan Investment Co., Ltd. *
(深圳市百业源投资有限公司) | 895,653,653 | Ordinary shares
denominated in Renminbi | 895,653,653 | | Hong Kong Securities Clearing Company
Limited | 127,833,815 | Ordinary shares
denominated in Renminbi | 127,833,815 | | Might Seasons Limited | 57,487,434 | Ordinary shares
denominated in Renminbi | 57,487,434 | | 108 portfolio of national social security fund | 11,461,721 | Ordinary shares
denominated in Renminbi | 11,461,721 | | Huaxia Life Insurance Co., Ltd. - proprietary
fund | 9,275,718 | Ordinary shares
denominated in Renminbi | 9,275,718 | | 16011 portfolio of basic endowment insurance
fund | 9,050,234 | Ordinary shares
denominated in Renminbi | 9,050,234 | | Bosera Funds Management Co., Ltd. - 419
portfolio of social security funds | 8,732,946 | Ordinary shares
denominated in Renminbi | 8,732,946 | | He Zhong | 7,800,024 | Ordinary shares
denominated in Renminbi | 7,800,024 | | Abu Dhabi Investment Authority | 5,417,816 | Ordinary shares
denominated in Renminbi | 5,417,816 | | Agricultural Bank of China Limited - China
500 Exchange Traded Open-End Index
Securities Investment Fund (ETF) | 4,690,194 | Ordinary shares
denominated in Renminbi | 4,690,194 | | Description of connection or acting-in-concert
relationship of the above shareholders | There was no connection or acting-in-concert relationship between
Shenzhen Baiyeyuan Investment Co., Ltd., the controlling shareholder
of the Company, and other shareholders; whether there is connection or
acting-in-concert relationship among other shareholders is unknown. | | | | Description of the participation of the top 10
shareholders and the top 10 shareholders
without selling restriction in securities margin
trading and securities financing (if any) | Shareholder He Zhong held 800,000 shares through an ordinary
securities account and 7,000,024 shares through a customer's margin
account, namely 7,800,024 shares in total. | | | | Notes on the special repurchase account among
the top 10 shareholders | As at the end of the Reporting Period, the special repurchase account of
the Company (special securities repurchase account of Joincare
Pharmaceutical Group Industry Co., Ltd.) owned 38,402,584 shares in
total, accounting for 2.01% of total share capital of the Company. | | |
III Other Information
Other key information on the operations of the Company during the Reporting Period to which investors should be reminded to pay attention
√Applicable □N/A
1.Use of proceeds
Pursuant to the “Resolution on Change of Certain Projects Invested with Proceeds” considered and approved at the 8th meeting of the 8th Session of the Board of the Company on 24 January 2022, it was agreed that Zhuhai Health Industry Base Construction Project was changed to the New Product R&D Project, Haibin Pharma Pingshan Pharmaceutical Industrialization Base Expansion Project and the Information Platform Construction Project. The resolution was approved at the 2022 1st extraordinary general meeting of the Company on 11 February 2022. Before the alteration of the projects invested with the Proceeds is as follows:
| Project name | Total
amount of
investment | Total amount
of proceeds
investment | Use of proceeds
as at 31
December 2021 | Balance of
proceeds as at 31
December 2021 | | Zhuhai Health Industry Base Construction
Project（珠海大健康产业基地建设项
目） | 98,066.84 | 76,974.02 | 3,386.29 | 73,587.73 | | Haibin Pharma Pingshan Pharmaceutical
Industrialization Base Project（海滨制药
坪山医药产业化基地目） | 125,471.35 | 90,000.00 | 66,745.58 | 23,254.42 | | Total | 223,538.19 | 166,974.02 | 70,131.87 | 96,842.15 |
Given the facts that the “Zhuhai Health Industry Base Construction Project” has been postponed for several times for not meeting the conditions for commencement, and the market environment and the Company's business situation have changed, which resulted in changes in the project feasibility, that the Company has an urgent need of funds for R&D investment and other projects, and that other financing channels are time-consuming and costly, the Company changed the aforementioned project to the New Product R&D Project, Haibin Pharma Pingshan Pharmaceutical Industrialization Base Expansion Project and the Information Platform Construction Project. See below for details:
Unit: 10,000 Yuan
| Before alteration | | | After alteration | | | | Project name | Total
amount of
investment | Total amount
of proceeds
investment | Project name | Total amount
of investment | Total
amount of
proceeds
investment | | Zhuhai Health
Industry Base
Construction Project
（珠海大健康产业
基地建设项目） | 98,066.84 | 76,974.02 | New Product R&D Project
(新产品研发项目) | 110,000.00 | 54,587.73 | | | | | Haibin Pharma Pingshan
Pharmaceutical
Industrialization Base
Expansion Project (海滨制
药坪山医药产业化基地扩
建项目) | 18,139.39 | 16,000.00 | | | | | The Information Platform
Construction Project (信息
化平台建设项目) | 3,000.00 | 3,000.00 | | Total | 98,066.84 | 76,974.02 | Total | 131,139.39 | 73,587.73 |
The details of alteration of the projects invested as follows: (1) The New Product R&D Project
The total investment amount of the project is RMB 1,100,000,000, in which RMB 545,877,300 is raised, mainly for the research and development of inhalation preparations, complex injections, and new drug delivery devices among others. In particular, the investment is used to acquire R&D equipment, pre-clinical and clinical R&D inputs. Main products involved in this project are: 1) Respiratory drugs: the main purpose of the project as a part of the Company's strategic layout in the
respiratory drug market, in a bid to increase sources of profit and enhance the Company's comprehensive competitiveness in the pharmaceutical market; 2) Complex injections: mainly micronano injections. The Company has built a complex injection technology development platform, specializing in the development of special injection products such as nanocrystals, microcrystals, liposomes and emulsions. The micronano preparations proposed with this platform will be developed based on existing drugs with exact clinical value to further expand the clinical use of the
drug; 3) New drug delivery devices: to be developed based on the progress of R&D of drugs for respiratory diseases, so as to improve the industrial chain of core products, and enhance the added
value and core competitiveness of products to be marketed.
(2) Haibin Pharma Pingshan Pharmaceutical Industrialization Base Expansion Project The total investment amount of this project is RMB 181,393,900, in which RMB 160,000,000 is raised. Expanded from the Haibin Pharma Pingshan Pharmaceutical Industrialization Base Expansion Project, this project established new production lines of Tobramycin Solution for Inhalation, Fluticasone Propionate Suspension for Inhalation, among others and expanded existing production lines of Budesonide Suspension for Inhalation and Levosalbutamol Hydrochloride Nebuliser Solution. This project is implemented for two key reasons: 1) New products are to be marketed, which requires related production lines. With inhalation preparations incorporated in its
key layout in recent years, the Company has continuously invested in the R&D of several new products with high clinical value and broad market space. As new products like Tobramycin Solution for Inhalation and Fluticasone Propionate Suspension for Inhalation are to be marketed, related production lines are necessary to make preparation for commercial production. 2) The capacity is unable to meet demand of some products: Budesonide Suspension for Inhalation was involved in the fifth batch of national centralized drug procurement in June 2021, and will be supplied to public hospitals in 7 domestic provinces, meeting 70% of the drug needs according to policies. Levosalbutamol Hydrochloride Nebuliser Solution is the first approved exclusive generic drug in China. As at the date the resolution got approved (January 24, 2022), no originator manufacturers or other generic drug manufacturers have been approved for market in China. However, the market demand is huge. The original capacity of the above two products is unable to meet such market demand, making capacity expansion a must.
(3) The Information Platform Construction Project
The total investment amount of this project is RMB 30,000,000, in which RMB 30,000,000 is raised. The investment is used to purchase information management software and hardware as well as computer room facilities. The project planned to upgrade and improve: the information infrastructure of existing information management system, including disaster recovery and infrastructure of the server, and security equipment; financial management system, including financial sharing system and tax administration system; group management and control system, including HR system and SAP system.
2. Matters about share repurchase
Pursuant to the Resolution on Share Repurchase Scheme by Way of Centralized bidding transactions and other resolutions considered and approved at the 6th Meeting of the 8th Session of
the Board and the 2021 Fifth Extraordinary General Meeting of the Company on 6 December 2021 and 23 December 2021, it was approved that the Company repurchased company shares by way of Centralized bidding transactions with its own funds; the total amount of repurchase funds should be
no less than RMB 300 million (inclusive) and no more than RMB 600 million (inclusive); the repurchase price should be no more than RMB 15/share (inclusive); the repurchase term should be no more than 12 months from the date when the repurchase scheme was approved by the General Meeting of the Company. For the details, please see the Announcement of Joincare Pharmaceutical Group Industry Co., Ltd. on the Share Repurchase Scheme by Way of Centralized bidding transactions (Lin 2021-145) and the Repurchase Report of Joincare Pharmaceutical Group Industry Co., Ltd. on Share Repurchase by Way of Centralized bidding transactions (Lin 2022-002). On 20 January 2022, the Company initially repurchased 785,992 shares by way of Centralized bidding transactions, representing 0.04% of total share capital (1,907,727,908 shares) of the Company. The aggregate amount of funds used for the repurchase was RMB 9.981 million (including the transaction costs). See the Announcement of Joincare Pharmaceutical Group Industry Co., Ltd. on Initial Share Repurchase by Way of Centralized bidding transactions (Lin 2022-004) for details. As of 31 March 2022, the Company initially repurchased 20,942,771 shares by way of Centralized bidding transactions, representing 1.10% of total share capital (1,911,733,078 shares) of the Company. The aggregate amount of funds used for the repurchase was RMB 249.97 million (including the transaction costs). See the Announcement of Joincare Pharmaceutical Group Industry Co., Ltd. on the Repurchase Progress by way of Centralized bidding transactions (Lin 2022-037) for details.
3. Matters about Equity Incentives
During the period from 1 January 2022 to 31 March 2022, 4,005,170 shares were granted by way of independent exercise and registered at the Shanghai Branch of China Securities Depository and Clearing Corporation Limited with a total of RMB 32,227,676.96 been paid. As of 31 March 2022, the Company's registered capital after change was RMB 1,911,733,078 and its share capital was RMB 1,911,733,078, of which, tradable shares subject to selling restrictions were RMB 0, representing 0% of the Company's registered capital, and tradable shares subject to no selling restrictions were RMB 1,911,733,078, representing 100% of the Company's registered capital. The exercise exerted no material impact on the financial conditions and operating results of the Company.
See the Announcement on 2022 Q1 Independent Exercise Results of the 2018 Share Options Incentive Scheme of Joincare Pharmaceutical Industry Group Co., Ltd. & Changes in Shares (Lin 2022-038) for details.
IV Quarterly Financial Statements
（I）Audit Opinion
□Applicable √N/A
（II）Financial statements
Consolidated Balance Sheet Statement
31 March 2022
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit type: Unaudited
| Item | 31 March 2022 | 31 December 2021 | | Current assets: | | | | Monetary funds | 12,579,072,007.38 | 11,729,230,390.98 | | Financial assets held for trading | 130,554,453.78 | 184,638,344.31 | | Bills receivable | 2,221,923,260.75 | 1,977,286,022.02 | | Accounts receivable | 2,897,888,908.52 | 2,853,655,551.54 | | Receivable financing | | | | Prepayments | 464,654,180.19 | 369,232,546.29 | | Other receivables | 80,180,643.34 | 88,053,825.12 | | In which: Interests receivable | 362,924.63 | 365,873.64 | | Dividends receivable | | | | Inventories | 2,029,375,758.07 | 2,078,944,387.68 | | Contract assets | | | | Held-for-sale assets | | | | Non-current assets due within one year | 317,381.23 | 317,381.23 | | Other current assets | 83,883,266.43 | 83,986,214.37 | | Total current assets | 20,487,849,859.69 | 19,365,344,663.54 | | Non-current assets: | | | | Debt investment | | | | Other debt investment | | | | Long-term receivables | 266,904.13 | 266,904.13 | | Long-term equity investment | 1,447,659,314.56 | 1,419,349,454.84 | | Other equity instrument investment | 1,186,338,011.05 | 1,408,882,377.42 | | Other non-current financial assets | | | | Investment properties | 6,191,475.43 | 6,191,475.43 | | Fixed assets | 4,779,625,073.08 | 4,839,005,169.81 | | Construction in progress | 903,828,896.94 | 742,998,743.75 | | Productive biological assets | | | | Oil & gas assets | | | | Right-of-use assets | 51,560,715.90 | 46,774,759.69 | | Intangible assets | 488,051,308.06 | 456,782,094.80 | | Development expenses | 846,825,404.25 | 786,993,435.71 | | Goodwills | 614,468,698.73 | 614,468,698.73 | | Long-term prepaid expenses | 196,182,282.29 | 200,715,740.93 | | Deferred income tax assets | 548,328,553.88 | 552,542,866.71 | | Other non-current assets | 717,916,255.16 | 663,584,003.80 | | Total non-current assets | 11,787,242,893.46 | 11,738,555,725.75 | | Total assets | 32,275,092,753.15 | 31,103,900,389.29 | | Current liabilities: | | | | Short-term loans | 1,655,807,901.10 | 2,518,484,835.09 | | Financial liabilities held for trading | 211,410.89 | 143,302.24 | | Bills payable | 1,871,975,736.48 | 1,582,386,767.93 | | Accounts payable | 846,260,427.00 | 871,553,210.51 | | Receipts in advance | 23,724,198.29 | | | Contract liabilities | 124,089,632.31 | 234,140,702.29 | | Payroll payable | 323,791,427.31 | 475,430,823.20 | | Taxes payable | 382,548,978.08 | 270,618,183.41 | | Other payables | 3,514,175,791.66 | 3,292,407,989.79 | | In which: Interests payable | | | | Dividends payable | 6,951,984.46 | 6,951,984.46 | | Held-for-sale liabilities | | | | Non-current liabilities due within one year | 93,590,946.07 | 91,576,066.33 | | Other current liabilities | 10,663,325.14 | 15,626,224.29 | | Total current liabilities | 8,846,839,774.33 | 9,352,368,105.08 | | Non-current liabilities: | | | | Long-term loans | 1,816,661,809.48 | 826,780,252.78 | | Bonds payable | | | | Lease liabilities | 27,215,133.45 | 25,071,794.32 | | Long-term payables | | | | Long-term payroll payable | | | | Estimated liabilities | | | | Deferred income | 486,773,175.06 | 433,543,352.40 | | Deferred income tax liabilities | 179,242,425.75 | 208,525,905.39 | | Other non-current liabilities | 84,000,000.00 | 78,000,000.00 | | Total non-current liabilities | 2,593,892,543.74 | 1,571,921,304.89 | | Total liabilities | 11,440,732,318.07 | 10,924,289,409.97 | | Owners’ equity (shareholders’ equity): | | | | Paid-in capital (or equity capital) | 1,911,733,078.00 | 1,907,727,908.00 | | Other equity instruments | | | | In which: Preferred shares | | | | Perpetual capital securities | | | | Capital reserve | 2,303,238,441.65 | 2,265,357,311.92 | | Less: Treasury shares | 472,590,296.96 | 222,644,454.50 | | Other comprehensive income | -87,498,451.08 | 5,387,545.97 | | Special reserve | | | | Surplus reserve | 650,230,145.70 | 640,821,179.08 | | Undistributed profits | 7,768,862,679.28 | 7,223,644,166.22 | | Total owners' equity (shareholders’ equity)
attributable to the parent company | 12,073,975,596.59 | 11,820,293,656.69 | | Minority shareholders' equity | 8,760,384,838.50 | 8,359,317,322.63 | | Total owners' equity (shareholders’ equity) | 20,834,360,435.08 | 20,179,610,979.32 | | Total liabilities and owners' equity (shareholders’
equity) | 32,275,092,753.15 | 31,103,900,389.29 |
Person-in-charge of the Person-in-charge of the Person-in-charge of the Company: Zhu Baoguo Company’s accounting work: accounting department: Qiu Qingfeng Qiu Qingfeng
Consolidated income statement
From January to March 2022
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit type: Unaudited
| Item | 2022 Jan.-Mar. | 2021 Jan.-Mar. | | I. Total operating revenues | 4,657,343,538.89 | 4,144,871,763.27 | | In which: Operating revenues | 4,657,343,538.89 | 4,144,871,763.27 | | II. Total operating costs | 3,650,160,694.91 | 3,314,653,870.26 | | In which: Operating costs | 1,611,006,712.60 | 1,448,371,494.49 | | Operating tax and surcharges | 52,198,225.41 | 50,752,537.45 | | Selling expenses | 1,413,289,256.99 | 1,342,825,512.04 | | Administrative expenses | 252,854,561.35 | 223,288,755.24 | | R&D expenses | 351,331,244.23 | 289,399,163.64 | | Finance expenses | -30,519,305.67 | -39,983,592.60 | | In which: Interest expenses | 29,854,923.66 | 15,859,568.04 | | Interest income | 68,468,649.16 | 40,497,552.32 | | Add: Other income | 59,138,624.91 | 77,577,799.31 | | Investment incomes (enter "-" for loss) | 29,176,808.52 | 21,812,732.70 | | In which: Income from investment in
associates and joint ventures | 15,204,632.53 | -1,982,728.44 | | Income from derecognition of financial
assets at amortized cost | | | | Net exposure hedging gains (enter "-" for
loss) | | | | Income from changes in fair value (enter "-"
for loss) | -54,151,999.18 | -39,393,074.92 | | Credit impairment loss (enter "-" for loss) | 217,773.10 | -3,611,272.93 | | Asset impairment loss (enter "-" for loss) | -5,309,013.21 | -22,802,167.34 | | Profit on disposal of assets (enter "-" for
loss) | -370,357.71 | 21,927.78 | | III. Operating profit (enter "-" for loss) | 1,035,884,680.41 | 863,823,837.62 | | Add: Non-operating income | 2,321,933.96 | 24,072,371.67 | | Less: Non-operating expenditures | 2,084,578.34 | 3,257,611.14 | | IV. Total profit (enter "-" for total loss) | 1,036,122,036.03 | 884,638,598.15 | | Less: Income tax expenses | 173,764,775.30 | 126,802,840.14 | | V. Net profit (enter "-" for net loss) | 862,357,260.73 | 757,835,758.01 | | (1) Classified by continuing operations | | | | 1. Net profit from continuing operations (enter "-"
for net loss) | 862,357,260.73 | 757,835,758.01 | | 2. Net profit from discontinuing operations (enter
"-" for net loss) | | | | (2) Classified by attribution to ownership | | | | 1. Net profit attributable to shareholders of the
parent company (enter "-" for net loss) | 460,537,813.53 | 366,890,019.20 | | 2. Profit and loss attributable to minority interests
(enter "-" for net loss) | 401,819,447.20 | 390,945,738.81 | | VI. Other comprehensive net income after taxation | -106,847,774.60 | -166,618,134.73 | | (1) Other comprehensive net income after taxation
attributable to shareholders of the parent company | -92,885,997.05 | -98,483,184.70 | | 1. Other comprehensive income not to be
reclassified into profit and loss | -75,513,312.70 | -81,219,999.41 | | 1) Changes in re-measurement of defined benefit
plans | | | | 2) Other comprehensive income not to be
reclassified into profit and loss under the equity
method | | | | 3) Changes in fair value of other equity instrument
investment | -75,513,312.70 | -81,219,999.41 | | 4) Changes in fair value of corporate credit risks | | | | 2. Other comprehensive income to be reclassified
into profit and loss | -17,372,684.35 | -17,263,185.29 | | 1) Other comprehensive income to be reclassified
into profit and loss under the equity method | | | | 2) Changes in fair value of other debt investment | | | | 3) Amount of financial assets reclassified into
other comprehensive income | | | | 4) Provision for credit impairment of other debt
investment | | | | 5) Cash flow hedge reserve | | | | 6) Foreign currency translation differences | -17,372,684.35 | -17,263,185.29 | | 7) Others | | | | (2) Other comprehensive net income after taxation
attributable to minority interests | -13,961,777.55 | -68,134,950.03 | | VII. Total comprehensive income | 755,509,486.13 | 591,217,623.29 | | (1) Total comprehensive income attributable to
shareholders of the parent company | 367,651,816.48 | 268,406,834.51 | | (2) Total comprehensive income attributable to
minority interests | 387,857,669.65 | 322,810,788.78 | | VIII. Earnings per share | | | | (1) Basic earnings per share (RMB/share) | 0.2411 | 0.1877 | | (2) Diluted earnings per share (RMB/share) | 0.2410 | 0.1872 |
Person-in-charge of the Person-in-charge of the Person-in-charge of the Company: Zhu Baoguo Company’s accounting work: accounting department: Qiu Qingfeng Qiu Qingfeng （未完）
|
|
